Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
Completed · Phase 3 · Has a placebo group
Conditions studied: Acute Coronary Syndromes
In brief
The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.
Key facts
- Study ID
- NCT00714961
- Run by
- Sanofi
- People needed
- 3491
- Starts
- 2003-02-01
- Expected to finish
- 2005-01-01
- Last updated by the study team
- 2009-03-25
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- STEMI within 12 hours of randomization
- Planned treatment with a fibrinolytic agent and aspirin
You may not qualify if…
- Intention of performing coronary angiography within 48 hours of fibrinolysis
- Treatment with clopidogrel or ticlopidine within 7 days prior to enrollment, or planned treatment with clopidogrel or ticlopidine.
- Contraindication to fibrinolysis
- Planned use of a glycoprotein IIb/IIIa inhibitor
- Prior CABG
- Evidence of cardiogenic shock or acute pulmonary edema requiring intubation or an intraaortic balloon pump
- Known renal or hepatic insufficiency
Where it is running
- Sanofi-Aventis — Bridgewater, New Jersey, United States
- Sanofi-Aventis — Buenos Aires, Argentina
- Sanofi-Aventis — Macquarie Park, Australia
- sanofi-aventis Austria — Vienna, Austria
- sanofi-aventis Belgium — Diegem, Belgium
- sanofi-aventis Brazil — São Paulo, Brazil
- sanofi-aventis Canada — Laval, Canada
- sanofi-aventis France — Paris, France
- sanofi-aventis Germany — Berlin, Germany
- Sanofi-Aventis Hungaria — Budapest, Hungary
- Sanofi-Aventis — Dublin, Ireland
- Sanofi-Aventis — Netanya, Israel
- sanofi-aventis Italy — Milan, Italy
- Sanofi-Aventis Mexico — México, Mexico
- sanofi-aventis Netherlands — Gouda, Netherlands
- sanofi-aventis Poland — Warsaw, Poland
- Sanofi-Aventis — Porto, Portugal
- Sanofi-Aventis — San Juan, Puerto Rico
- Sanofi-Aventis — Moscow, Russia
- sanofi-aventis South Africa — Midrand, South Africa
- sanofi-aventis Spain — Barcelona, Spain
- sanofi-aventis Sweden — Bromma, Sweden
- Sanofi-Aventis — Istanbul, Turkey (Türkiye)
- sanofi-aventis UK — Guildford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.